ArticleWorld journal of psychiatry2025
Efficacy of electroacupuncture for cervical spondylosis-related pain in patients with generalized anxiety disorder.
Article in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical spondylosis (CS) frequently co-occurs with generalized anxiety disorder (GAD), presenting a complex clinical challenge. Managing CS-related pain in patients with GAD is particularly challenging because of the bidirectional relationship between pain and anxiety, necessitating integrated treatment strategies.
aimTo evaluate the efficacy of electroacupuncture (EA) in treating CS-related pain and anxiety in patients with GAD.
methodsThis retrospective cohort study analyzed data from 83 patients with CS-related pain and GAD who received EA treatment over 2-year period. Pain intensity was assessed using the visual analog scale, and anxiety symptoms were measured using the Hamilton Anxiety Rating Scale. Additionally, neuroinflammatory markers, including interleukin-6, tumor necrosis factor-alpha, and high-sensitivity C-reactive protein, were examined. Outcomes were evaluated at baseline, after 4 weeks, and after 8 weeks of treatment.
resultsEA treatment significantly reduced CS-related pain (mean visual analog scale reduction: 3.24 ± 1.18;
conclusionEA demonstrates significant efficacy in reducing CS-related pain in patients with comorbid GAD, along with concurrent improvements in anxiety symptoms and neuroinflammatory profiles. These findings suggest that EA may offer a valuable integrative approach for managing this complex clinical presentation, potentially addressing both pain and anxiety through the modulation of neuroinflammatory pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.